The NY Times reports that a federal judge on Monday struck down patents on two genes linked to breast and ovarian cancer. The decision, if upheld, could throw into doubt the patents covering thousands of human genes and reshape the law of intellectual property.
U.S. Judge Invalidates Human Gene Patent
2 Comments
Recent Posts
Senate Bill Would Grant Government Regulatory Power to Mandate Age Verification For Search, Social Media and AI Services Accompanied By Threat of Court Ordered Blocking of Lawful Content 
Government Reverses on Bill C-2: Removes Lawful Access Warrantless Demand Powers in New Border Bill 
Why The Recent TikTok Privacy Ruling Swaps Privacy for Increased Surveillance 
The Law Bytes Podcast, Episode 245: Kate Robertson on Bill C-2’s Cross-Border Data Sharing Privacy Risks 
The Law Bytes Podcast, Episode 244: Kris Klein on the Long Road to a Right to be Forgotten Under Canadian Privacy Law
“Myriad Genetics, the company that holds the patents with the University of Utah Research Foundation, asked the court to dismiss the case, claiming that the work of isolating the DNA from the body transforms it and makes it patentable. ”
So, they claim they aren’t actually patenting the two genes, they are patenting transformed version of the genes? To me this would invalidate the work of the human genome project, as they cataloged not the human genome but some variation thereof… Or am I understanding the claim incorrectly?
They’re claiming that isolated DNA is “transformed”, so the not-found-in-nature requirement of a patent doesn’t apply to the genes.